Abstract

In 2008, the U.S. market for drug eluting stents was valued at $1.95 billion, representing an increase of 1.6% over 2007. Overall average selling prices are predicted to decrease over the forecast period. Additional products included in this report: Bioabsorbable Stents, Bifurcated Stentsand bare-metal stents.

TABLE OF CONTENTS

U.S. MARKET FOR DRUG-ELUTING AND BARE METAL STENTS 2009.I
TABLE OF CONTENTS. II
LIST OF FIGURESV
LIST OF CHARTSVI
EXECUTIVE SUMMARY 1
1.1 MARKET FOR INTERVENTIONAL CARDIOLOGY DEVICES  1
1.2 BARE-METAL AND DRUG-ELUTING STENTS  1
1.3 PTCA AND CUTTING BALLOONS 1
1.4 BALLOON-INFLATION SYRINGES AND ANGIOPLASTY KITS  2
1.5 INTERVENTIONAL CATHETERS  2
1.6 INTERVENTIONAL GUIDEWIRES 2
1.7 EMBOLIC PROTECTION DEVICES  3
1.8 ATHERECTOMY DEVICES 3
1.9 THROMBECTOMY DEVICES 4
1.10 CHRONIC TOTAL OCCLUSION CROSSERS  4
1.11 INTRODUCER SHEATHS 5
1.12 VASCULAR CLOSURE DEVICES 5
1.13 DIAGNOSTIC CORONARY CATHETERS AND GUIDEWIRES  6
1.14 FRACTIONAL FLOW RESERVE GUIDEWIRES  7
1.15 IVUS CATHETERS 8
1.16 OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES  9
1.17 VULNERABLE PLAQUE DEVICES 10
1.18 PFO, ASD AND VSD DEVICES  10
1.19 PERCUTANEOUS MITRAL VALVE REPAIR DEVICES 10
1.20 AORTIC HEART VALVE REPLACEMENT DEVICES 10
1.21 LEADING COMPETITORS  11
RESEARCH METHODOLOGY 13
2.1 RESEARCH SCOPE  13
2.2 9-STEP METHODOLOGY  13
2.2.1 Step 1: Project Initiation & Team Selection  14
2.2.2 Step 2: Prepare Data Systems and Perform Secondary Research 15
2.2.3 Step 3: Preparation for Interviews & Questionnaire Design  16
2.2.4 Step 4: Performing Primary Research 17
2.2.5 Step 5: Research Analysis: Establishing Baseline Estimates  19
2.2.6 Step 6: Market Forecast and Analysis  19
2.2.7 Step 7: Identify Strategic Opportunities  21
2.2.8 Step 8: Final Review and Market Release  22
2.2.9 Step 9: Customer Feedback and Market Monitoring 23
BARE-METAL AND DRUG-ELUTING STENTS 24
3.1 INTRODUCTION  24
3.2 POPULATION AT RISK  26
3.3 PROCEDURE NUMBERS  30
3.4 MARKET ANALYSIS & FORECAST . 32
3.4.1 Units Sold by Type  35
3.4.2 Bare-Metal Stent Market . 37
3.4.2.1 Bare-Metal Stent Market Drivers 39
3.4.2.2 Bare-Metal Stent Market Limiters 39
3.4.3 Drug-Eluting Stent Market  41
3.4.3.1 Drug-Eluting Stent Market Drivers 44
3.4.3.2 Drug-Eluting Stent Market Limiters 45
3.4.4 Stents in Development 47
3.4.4.1 Bioabsorbable Stents 48
3.4.4.2 Bifurcated Stents50
3.5 STENT MARKET BY DELIVERY PLATFORM 52
3.6 STENT MARKET BY SIZE. 54
3.7 COMPETITIVE ANALYSIS  56
3.7.1 Bare-Metal Stents  56
3.7.2 Drug-Eluting Stents  58
3.7.3 Potential New Market Participants . 62
ABBREVIATIONS 65

LIST OF FIGURES
EXECUTIVE SUMMARY 1
RESEARCH METHODOLOGY 13
BARE-METAL AND DRUG-ELUTING STENTS 24
Figure 4-1: Population at Risk, Market for Interventional Cardiology, U.S., 2005-2015  27
Figure 4-2: Angiography and Angioplasty Procedures, U.S., 2005-2015. 30
Figure 4-3: Market for Coronary Stents by Type, U.S., 2005-2015 33
Figure 4-4: Units Sold, Market for Coronary Stents, U.S., 2005-2015  35
Figure 4-5: Coronary Stent Units by Type, U.S., 2005-2015 . 36
Figure 4-6: Market for Bare-Metal Stents, U.S., 2005-2015  37
Figure 4-7: Market Drivers and Limiters, Market for Bare-Metal Stents, U.S.,
2008  40
Figure 4-8: Market for Drug-Eluting Stents, U.S., 2005-2015 . 42
Figure 4-9: Market Drivers and Limiters, Market for Drug-Eluting Stents, U.S.,
2008  46
Figure 4-10: Coronary Stent Platforms in Development Not Approved by the
FDA, 2008. 47
Figure 4-11: Potential Market for Bioabsorbable Stents, U.S., 2013-2015 . 49
Figure 4-12: Potential Market for Bifurcated Stents, U.S., 2010-2015  51
Figure 4-13: Market for Coronary Stents by Delivery Platform, Units Sold, U.S.,
2005-2015 52
Figure 4-14: Market for Coronary Stents by Size, U.S., 2008  54
Figure 4-15: Leading Competitors, Market for Bare-Metal Stents, U.S., 2008  57
Figure 4-16: Leading Competitors, U.S. Market for Drug-Eluting Stents, 2008  60
ABBREVIATIONS  65

LIST OF CHART S
EXECUTIVE SUMMARY 1
Chart 1-1: Market for Interventional Cardiology Devices, U.S., 2008  1
Chart 1-2: Market for Coronary Stents, U.S., 2005-2015. 1
Chart 1-3: Coronary Atherectomy Devices Market, U.S., 2005-2015 3
Chart 1-4: Coronary CTO Crosser Market, U.S., 2005-2015  4
Chart 1-5: Coronary Vascular Closure Devices, U.S., 2005-2015 . 5
Chart 1-6: Market for Diagnostic Coronary Catheters and Guidewires, U.S., 2005-2015  6
Chart 1-7: Penetration Rate of FFR Guidewires in PCI Procedures, U.S., 2005-2015  7
Chart 1-8: Number of IVUS Catheter Units Sold, U.S., 2005-2015 8
Chart 1-9: Optical Coherence Tomography Catheter Market, U.S., 2010-2015  9
Chart 1-10: Leading Competitors, Market for Interventional Cardiology, U.S.,
2008  11
RESEARCH METHODOLOGY 13
BARE-METAL AND DRUG-ELUTING STENTS 24
Chart 4-1: Population at Risk, Market for Interventional Cardiology, U.S., 2005-2015  28
Chart 4-2: Age Group Most Likely to Undergo Cardiac Intervention: 60 to 69
Years Old, U.S., 2005-2015. 29
Chart 4-3: Angioplasty and Angiography Procedures, U.S., 2005-2015  31
Chart 4-4: Market for Coronary Stents by Type, U.S., 2005-2015  34
Chart 4-5: Coronary Stent Units by Type, U.S., 2005-2015 36
Chart 4-6: Market for Bare-Metal Stents, U.S., 2005-2015 38
Chart 4-7: Market for Drug-Eluting Stents, U.S., 2005-2015. 43
Chart 4-8: Penetration Rate for Bioabsorbable Stents, U.S., 2013-2015 49
Chart 4-9: Penetration Rate for Bifurcated Stents, U.S., 2010-2015  51
Chart 4-10: Market for Coronary Stents by Delivery Platform, Units Sold, U.S.,
2005-2015 53
Chart 4-11: Market for Coronary Stents by Size, U.S., 2008  55
Chart 4-12: Leading Competitors, Market for Bare-Metal Stents, U.S., 2008  57
Chart 4-13: Leading Competitors, Market for Drug-Eluting Stents, U.S., 2008  61
ABBREVIATIONS  65